The functions of the xenograft Core are: 1. The purpose of this Core is to provide a facility for the propagation of xenografts of pediatric solid tumors, for use in all Projects. The standard model will comprise tumor growing in the subcutaneous space of female severe combined immunodefiecient (SCID) mice. 2. Coordinate tumor transplantation and make available tumor-bearing mice for biochemical and pharmacokinetic studies as required. 3. Undertake drug evaluation studies using standardized protocols. Data will be accessed directly into a microcomputer, and information distributed on a regular basis to individual project leaders, and to the Biostatistics Core for analysis. 4. Establish models of minimal residual disease for evaluating both cytotoxic and novel approaches to tumor eradication (e.g. gene therapy/antisense). 5. Develop models of disseminated disease as a secondary screen for drug evaluation. 6. Develop disseminated disease models with luciferase reporters for DNA damage, hypoxia, to monitor tumor growth, spread and drug-response using non-invasive techniques (Xenogen system). 7. Maintain and characterize human xenografts,, and maintain frozen stocks. 8. Provide services (e.g. blood collection, 1 to 5 day infusions in mice). 9. To evaluate transgenic tumor models where requested.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA023099-33
Application #
8309818
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2011-08-01
Project End
2013-07-31
Budget Start
2011-08-01
Budget End
2013-07-31
Support Year
33
Fiscal Year
2011
Total Cost
$317,882
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Dowless, Michele; Lowery, Caitlin D; Shackleford, Terry et al. (2018) Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling. Clin Cancer Res 24:6028-6039
Bishop, Michael W; Advani, Shailesh M; Villarroel, Milena et al. (2018) Health-Related Quality of Life and Survival Outcomes of Pediatric Patients With Nonmetastatic Osteosarcoma Treated in Countries With Different Resources. J Glob Oncol :1-11
Wang, Tingting; Liu, Lingling; Chen, Xuyong et al. (2018) MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent. Cell Death Dis 9:220
Feng, Helin; Tillman, Heather; Wu, Gang et al. (2018) Frequent epigenetic alterations in polycomb repressive complex 2 in osteosarcoma cell lines. Oncotarget 9:27087-27091
Hu, Dongli; Jablonowski, Carolyn; Cheng, Pei-Hsin et al. (2018) KDM5A Regulates a Translational Program that Controls p53 Protein Expression. iScience 9:84-100
Power-Hays, Alexandra; Friedrich, Paola; Fernandez, Gretchen et al. (2017) Delivery of radiation therapy in resource-limited settings: A pilot quality assessment study. Pediatr Blood Cancer 64:
Brennan, Rachel C; Qaddoumi, Ibrahim; Mao, Shenghua et al. (2017) Ocular Salvage and Vision Preservation Using a Topotecan-Based Regimen for Advanced Intraocular Retinoblastoma. J Clin Oncol 35:72-77
Yu, Peter Y; Gardner, Heather L; Roberts, Ryan et al. (2017) Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. PLoS One 12:e0181885
Yang, Jun; Milasta, Sandra; Hu, Dongli et al. (2017) Targeting Histone Demethylases in MYC-Driven Neuroblastomas with Ciclopirox. Cancer Res 77:4626-4638
D'Oto, Alexandra; Tian, Qing-Wu; Davidoff, Andrew M et al. (2016) Histone demethylases and their roles in cancer epigenetics. J Med Oncol Ther 1:34-40

Showing the most recent 10 out of 814 publications